Summit Therapeutics has a single clinical asset, ivonescimab, licensed exclusively from Akeso, with analysts projecting 102% upside and a risk-reward ratio of more than 10 to 1, but the quality score of 1.8, 27% short interest, and 3 consecutive earnings misses before the most recent quarter reflect the binary nature of the investment.
Thesis pillars
- Analyst Consensus 100pct Upside↓Deteriorating
- Ivonescimab Single Asset Binary→Stable
- High Short Interest Informed Bears→Stable
- +1 more pillar — see the Why tab for full reasoning
Summit Therapeutics Inc. (SMMT) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum.
Summit Therapeutics is a clinical-stage biopharmaceutical company with a single development candidate, ivonescimab, a PD-1/VEGF-A bispecific antibody licensed from Akeso Inc. in January 2023. Summit has no approved products or revenue; a BLA for ivonescimab in EGFR-mutated NSCLC... Read more
Sell if holding. Engine safety override at $14.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Score 5.1/10, moderate confidence.
Passes 7/10 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and news bankruptcy. Suitability: speculative.
About Summit Therapeutics Inc.
About Summit Therapeutics Inc.
Summit Therapeutics' entire pipeline rests on a single asset — ivonescimab, a PD-1/VEGF-A bispecific antibody licensed from Akeso Inc. in January 2023 for $474.9 million upfront in cash and stock. The company has no approved products and no revenue. The HARMONi Phase III trial demonstrated a PFS hazard ratio of 0.52 (p<0.00001) in EGFR-mutated NSCLC; a BLA was submitted in Q4 2025, accepted by FDA in January 2026, with PDUFA date of November 14, 2026.
Summit earns no product revenue and funds operations through capital markets. The license from Akeso covers commercialization rights in the United States, Canada, Europe, Japan, Latin America, Middle East, and Africa, while Akeso retains rights for China — where ivonescimab was approved by the NMPA in May 2024 for EGFR-mutated NSCLC in combination with chemotherapy and again in April 2025 as monotherapy for PD-L1 positive NSCLC. Akeso supplies drug substance and drug product under a supply agreement, and Summit pays a low-double-digit royalty on annual revenues plus milestone payments on regulatory approvals and commercial targets. Summit is running three additional Phase III trials — HARMONi-3 (first-line metastatic NSCLC vs. pembrolizumab), HARMONi-7 (high PD-L1 monotherapy vs. pembrolizumab), and HARMONi-GI3 (colorectal cancer) — with enrollment completions targeted between 2026 and 2027.
Show full overview
The PDUFA date of November 14, 2026 represents a binary regulatory event: the FDA noted that a statistically significant overall survival benefit is necessary to support marketing authorization in the EGFRm NSCLC 2L+ setting, yet the HARMONi primary analysis did not achieve statistical significance for OS (HR=0.79; p=0.057). Approval would initiate commercialization across the Licensed Territory; a Complete Response Letter would leave Summit with no approved product, no alternative revenue source, and ongoing Phase III spend across four concurrent trials.
See also: Healthcare · Biotechnology
From Summit Therapeutics Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-27Recent Developments — Summit Therapeutics Inc.
Latest news
- NEWS Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention — benzinga Jul 24, 2026 positive
- NEWS Summit Therapeutics Flags Going Concern Risk Over Cash Needs — benzinga Jul 24, 2026 negative
- NEWS Stifel Maintains Buy on Summit Therapeutics, Lowers Price Target to $38 — benzinga Jul 24, 2026 positive
- NEWS Guggenheim Maintains Buy on Summit Therapeutics, Lowers Price Target to $38 — benzinga Jul 24, 2026 neutral
- NEWS Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session — benzinga Jul 24, 2026 negative
Generated 2026-07-27T14:48:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineivonescimab10-K Item 1A: 'We depend heavily on the success of ivonescimab. If we are unable to successfully develop and commercialize ivonescimab, or experience significant delays in doing so'
- HIGHcounterpartyAkeso license10-K Item 1A: 'We depend on our relationship with, and the intellectual property licensed from Akeso'
- HIGHSupplierAkeso10-K Item 1A: 'We rely on the use of third parties, including Akeso, to manufacture our product candidate'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $13.11. Score 5.1/10, moderate confidence.
Take-profit target: $24.47 (+73.6% upside). Prior stop was $13.11. Stop-loss: $13.11.
Concentration risk — Pipeline: ivonescimab; Concentration risk — Counterparty: Akeso license; Quality below floor (2.2 < 4.0).
Summit Therapeutics Inc. trades at a P/E of N/A (forward -11.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover SMMT with a consensus score of 3.8/5. Average price target: $28.
What does Summit Therapeutics Inc. do?Summit Therapeutics is a clinical-stage biopharmaceutical company with a single development candidate, ivonescimab, a...
Summit Therapeutics is a clinical-stage biopharmaceutical company with a single development candidate, ivonescimab, a PD-1/VEGF-A bispecific antibody licensed from Akeso Inc. in January 2023. Summit has no approved products or revenue; a BLA for ivonescimab in EGFR-mutated NSCLC was accepted by the FDA in January 2026 with a PDUFA date of November 14, 2026.